the nitrogen atom of γ-butyrolactam to form an N-acyliminium
cation (intermediate) in a more stable system leading to a faster
reaction and giving a higher yield, while in aromatic aldehydes
containing EDG the formation of an N-acyliminium cation is
less stable leading to a slower reaction and lower yield.
substitution patterns, mild reaction conditions and a convenient
work-up.
Acknowledgements
We have evaluated in vitro anticancer activity for the syn-
thesized molecule at four different concentrations of 0.3 μM,
1 μM, 3 μM and 10 μM against a panel of five cancer cell lines.
The human tumor cell lines of renal cancer, pancreatic cancer,
lung cancer, colon cancer and normal breast epithelium of
MCF7 and MCF10A were used for evaluating anticancer activity
on the high throughput screening platform using Cell Counting
Kit (CCK8) cell proliferation and cytotoxicity assays.
The authors thank Dr Arun Balakrishnan, Vice President, Exter-
nal Liaison and Screening Piramal Life Sciences Limited,
Mumbai, for the anticancer screening.
Notes and references
1 (a) A. I. Meyers and L. Snyder, J. Org. Chem., 1993, 1, 36;
(b) C. M. Moody and D. W. Young, Tetrahedron Lett., 1994, 35, 7277;
(c) B. Rigo, D. Fasseur, N. Cherepy and Couturier, Tetrahedron Lett.,
1989, 30, 7057; (d) G. Poli, S. C. Baffoni, G. Giambastiani and
G. Renginato, Tetrahedron, 1998, 54, 10403.
A preliminary screening showed that some of the derivatives
exhibited moderate to strong anticancer activity on various
cancer cell lines which have been shown in the ESI.†
2 (a) A. H. Gouliaev and A. Senning, Brain Res. Rev., 1994, 19, 180;
(b) E. J. Cory and F. Zhang, Org. Lett., 2000, 2, 4257; (c) R. Aslanian,
G. Lee, R. V. Iyer, N. Shih, J. J. Piwinski, R. W. Draper and
A. T. McPhail, Tetrahedron: Asymmetry, 2000, 11, 3867; (d) A.
S. Paraskar and A. Sudalai, Tetrahedron, 2006, 62, 4907.
3 (a) J. K. Whitesell, Chem. Rev., 1989, 89, 1581; (b) E. Arvanitis,
M. Motevalli and P. B. Wyatt, Tetrahedron Lett., 1996, 37, 4277;
(c) D. Ma and J. Jiang, Tetrahedron: Asymmetry, 1998, 9, 575.
4 (a) A. Domling, Chem. Rev., 2006, 106, 17; (b) E. Ruijter, R. Scheffelaar
and R. V. A. Orru, Angew. Chem., Int. Ed., 2011, 50, 6234;
(c) L. F. Tietze, G. Brasche and K. Gericke, Domino Reactions in
Organic Synthesis, John Wiley-VCH, Weinheim, 2006, 542–565;
(d) B. Ganem, Acc. Chem. Res., 2009, 42, 463; (e) M. Li, Z. Zuo, L. Wen
and S. Wang, J. Comb. Chem., 2008, 10, 436; (f) N. K. Terrett, Combina-
torial Chemistry, Oxford University Press, New York, 1998;
(g) L. T. Tietza, Chem. Rev., 1996, 96, 115.
For those drug molecules that are active against cancer cells in
the preliminary screening, we studied their molecular stability in
stimulated gastric fluid11 and bovine serum albumin.12 SGF was
prepared according to the US Pharmacopeia (USP XII 1995).11a
BSA with high purity (>98%) was purchased from SRL Pvt. Ltd
which was made fatty acid free by using Norit12a and prepared
following the standard method.12b
The molecular stability was measured by UV-Visible spectra
(λ = 400–190 nm) for an interval of time in SGF and BSA as
shown in the ESI.† At different drug concentrations a linear cali-
bration curve was plotted under similar conditions from which
the sample concentrations were calculated.
The molecular stability was measured by the percentage of
concentration loss in comparison to the freshly prepared known
samples. Some of the drug molecules showed moderate to strong
stability towards SGF and BSA for 4–5 h. Detailed stability
studies of SGF and BSA for compounds 4b, 4f, 4g, 4i, 4j and
4m–o using UV-Visible spectra have been given in the ESI.†
We evaluated IC50 values of primary active compounds at 8
different concentrations (0.003 μM, 0.01 μM, 0.03 μM, 0.3 μM,
1 μM, 3 μM, 10 μM and 30 μM) to study the activity against
cancer cell lines at varied concentrations. The results revealed
that the compound 4i showed potent IC50 in the range of 0.6 μM
to 1.2 μM in cancer cells, while IC50 of normal breast epithelium
cells showed 14.87 μM for MCF10A and 1.2 μM for MCF7.
Hence, 4i was highly active towards proliferating cells and even
other compounds 4f, 4o and 4g were found to be potentially
active against cancer cell lines with less cytotoxicity on breast
cancer cells as well as normal epithelium cells. The results
obtained for the active analogues are reported in Table 3. In most
of the cases these analogues were found to possess good activity
against cancer cells, if aromatic aldehydes contain EWG.
In summary, we have successfully developed an efficient
synthetic protocol for a domino reaction of γ-butyrolactam, aro-
matic aldehydes and substituted thiophenols using iodine as a
catalyst. The Lewis acidity of iodine shows enormous catalytic
activity making it capable of binding with the carbonyl oxygen
of aldehyde to yield the desired product. These synthesized
pyrrolidone (4) analogues have been evaluated for their antican-
cer activity and their stability in SGF and BSA. A few of these
compounds were found to be effective against different cancer
cell lines. Thus we conclude that these reactions offer several
advantages such as readily available starting materials, flexible
5 (a) J. D. Sunderhaus, C. Dockendorff and S. F. Martin, Org. Lett., 2007,
9, 4223; (b) F. Lieby-Muller, T. Constantieux and J. Rodriguez, J. Am.
Chem. Soc., 2005, 49, 17176; (c) Y. K. Chen and P. J. Walsh, J. Am.
Chem. Soc., 2004, 126, 3702; (d) M. Zhang, H. Jiang, H. Liu and
Q. Zhu, Org. Lett., 2007, 21, 4111; (e) Y. Yamamoto, J. Ishii,
H. Nishiyama and K. Itoh, J. Am. Chem. Soc., 2004, 12, 3712;
(f) A. Dondoni, A. Massi, E. Minghini, S. Sabbtini and V. Bertolasi,
J. Org. Chem., 2003, 16, 6172.
6 (a) H. Zhou, A. Liu, X. Li, X. Ma, W. Feng, W. Zhang and B. Yan,
J. Comb. Chem., 2008, 10, 303; (b) I. Ugi, A. Domling and B. Werner,
J. Heterocycl. Chem., 2000, 37, 647; (c) R. E. Dolle, B. L. Bourdonnec,
A. J. Goodman, G. A. Morales, J. M. Salvino and W. Zhang, J. Comb.
Chem., 2007, 9, 855.
7 (a) D. J. Ramon and M. Yus, Angew. Chem., Int. Ed., 2005, 44, 1602;
(b) A. Ulaczyk-Lesanko and D. G. Hall, Curr. Opin. Chem. Biol., 2005,
9, 266.
8 (a) M. W. Haenel, J. Narangerel, U. B. Richter and A. Rufinska, Angew.
Chem., Int. Ed., 2006, 45, 1061; (b) C. Wan, L. Gao, Q. Wang, J. Zhang
and Z. Wang, Org. Lett., 2010, 17, 3902; (c) J. Sun, Y. Dong, L. Cao,
X. Wang, S. Wang and Y. Hu, J. Org. Chem., 2004, 69, 8932;
(d) X. F. Li, S. L. Cui and Y. G. Wang, Tetrahedron Lett., 2006, 47, 3127;
(e) Q. Xu and E. Rozners, Org. Lett., 2005, 14, 2821; (f) X. Wang, Q. Li,
J. Wu and S. Tu, J. Comb. Chem., 2009, 3, 433.
9 (a) P. Phukan, J. Org. Chem., 2004, 11, 4005; (b) B. Jiang, C. Li, S. Tu and
F. Shi, J. Comb. Chem., 2010, 4, 482; (c) L. Zeng and C. Cai, J. Heterocycl.
Chem., 2010, 47, 1035; (d) S. K. Sharma, A. K. Mandadapu, B. Kumar
and B. Kundu, J. Org. Chem., 2011, 76, 6798; (e) L. Zeng and C. Cai,
J. Comb. Chem., 2010, 12, 35; (f) D. Prajapati, D. Bhuyan, M. Gohain and
W. Hu, Mol. Diversity, 2011, 15, 257.
10 (a) H. Li, G. Ramachandran, V. Satheesh, K. Sathiyanarayanan and
R. S. Rathore, Acta Crystallogr., Sect. E: Struct. Rep. Online, 2012, E68,
0768; (b) H. Li, G. Ramachandran, M. Sathishkumar,
K. Sathiyanarayanan and R. S. Rathore, Acta Crystallogr., Sect. E: Struct.
Rep. Online, 2012, E68, 0782.
11 (a) B. M. Corcoran, C. Stanton, G. F. Fitzgerald and R. P. Ross, Appl.
Environ. Microbiol., 2005, 71, 3060; (b) D. Debanjan and L. Senshang,
J. Pharm. Sci., 2005, 94, 1343.
12 (a) F. C. Raymond, J. Biol. Chem., 1967, 242, 173; (b) P. M. Sankar,
J. Surf. Sci. Technol., 2007, 23, 91.
5346 | Org. Biomol. Chem., 2012, 10, 5343–5346
This journal is © The Royal Society of Chemistry 2012